Tag Archives: NASDAQ:MYGN

Myriad Genetics (MYGN) Gets a Hold Rating from Needham

In a report released today, Stephen Unger from Needham assigned a Hold rating to Myriad Genetics (MYGN – Research Report). The company’s shares closed last Thursday at $13.38, close to its 52-week low of $9.24. According to TipRanks.com, Unger is

Needham Releases a Hold Rating on Myriad Genetics (MYGN)

Needham analyst Stephen Unger assigned a Hold rating to Myriad Genetics (MYGN – Research Report) today. The company’s shares closed last Tuesday at $14.82, close to its 52-week low of $9.24. According to TipRanks.com, Unger is a 5-star analyst with

Myriad Genetics (MYGN) Gets a Sell Rating from Barclays

Barclays analyst Jack Meehan maintained a Sell rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $10.00. The company’s shares closed last Monday at $14.82, close to its 52-week low of $9.24. According to

A Director at Myriad Genetics (NASDAQ: MYGN) is Buying Shares

Today, a Director at Myriad Genetics (MYGN – Research Report), John Henderson, bought shares of MYGN for $164.2K. Following this transaction John Henderson’s holding in the company was increased by 2333.33% to a total of $1.54 million. See today’s analyst

Myriad Genetics (MYGN) Receives a Hold from Needham

In a report released today, Stephen Unger from Needham maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The company’s shares closed last Monday at $35.10. According to TipRanks.com, Unger is a 4-star analyst with an average return

Myriad Genetics (MYGN) Receives a Sell from Barclays

In a report released yesterday, Jack Meehan from Barclays maintained a Sell rating on Myriad Genetics (MYGN – Research Report), with a price target of $22. The company’s shares closed last Monday at $22.97, close to its 52-week low of